AVESTHAGEN LIMITED Appoints Two Independent Board Members
February 25, 2009: AVESTHAGEN LIMITED, India's leading knowledge based Life Sciences Company today announced the appointment of two new members to its board of directors. Avesthagen has a bioPharma, bioNutra, biAgri products pipeline and is currently working on bringing in early revenues by advancing licensing, partnership deals and re-strategising its business model. The company will be entering into strategic partnerships by monetising its operations at individual levels of research and development and patents. The new members on the board will play a key role in catalyzing this vision.
Tweet-- AVESTHAGEN LIMITED, India’s leading knowledge based Life Sciences Company today announced the appointment of two new members to its board of directors. Avesthagen has a bioPharma, bioNutra, biAgri products pipeline and is currently working on bringing in early revenues by advancing licensing, partnership deals and re-strategising its business model. The company will be entering into strategic partnerships by monetising its operations at individual levels of research and development and patents. The new members on the board will play a key role in catalyzing this vision.
Joining the board are:
Professor N.K Ganguly is the Advisor to Health Minister, Ministry of Health and Family Welfare, India. He is a distinguished biotechnology fellow and advisor at the Translational Health Science & Technology Institute. Professor Ganguly is the former Director General of the Indian Council of Medical Research in New Delhi. He has over four decades of experience in research and teaching. His areas of interest are Microbiology and Immunology.
David Atkinson is the Managing Director of Twenty Two North. He is a seed industry veteran with over three decades of experience and was the part of the International Seed Group Inc.
Professor N.K Ganguly, the Advisor to Health Minister, Ministry of Health and Family Welfare, India said, “The biotechnology space is extremely exciting. Avesthagen’s vision to focus on research and innovation to bring predictive and personalized medicine to the world is extremely commendable.”
Welcoming the new members, Professor N.K Ganguly and David Atkinson to the board, Dr. Villoo Morawala-Patell, Founder & CMD, Avesthagen Limited, said, “The new members bring with them diversity of experience and opinions from which the company will benefit. Their guidance will also provide direction to current research activities and help us in advancing licensing and partnership deals.”
Last year, Farah Patell and Sanaya Patell, both pursuing their Ph. D at the University of Cambridge were appointed as board members.
Notes to Editor
AVESTHAGEN LIMITED (www.avesthagen.com) is India’s leading integrated systems biology platform company that focuses on achieving convergence of food, pharma and population genetics leading to predictive preventive and personalized healthcare. It employs 450 people worldwide and is headquartered in Bangalore. Avesthagen Limited has established world class, state-of-the-art laboratory facilities in Bangalore. It began business operations in 2001.Since its inception Avesthagen has grown into one of India's leading healthcare technology group in India, and its activities include, in addition to its agri-biotechnologies product pipeline, development of clinically validated botanical bioActives, derived from Indian medicinal plants, as well as the development of a pipeline of bio-similar drugs. Avesthagen Limited has four strategic business units: bioPharmaceuticals, bioNutrition, bioAgriculture and Science & Innovation. Its partners include multiple top 10 global companies in each of its fields of research. Avesthagen Limited collaborates at every stage in the value chain with appropriate partners, both public and private, for access to and exchange of technology and overall commercial expertise to leverage the ‘India advantage’.